Post-Market Clinical Follow-up Study with ASPIREX®S to Assess the Safety and Effectiveness in the Treatment of DVT
Key facts
- Who runs it
- Straub Medical AG
- Where
- Austria, France, Germany, Ireland, and Italy9 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 81 people enrolled
- Started
- 3 Apr 2017
- Ended
- 6 Jun 2024
- Type of study
- Observational
- Record updated
- 3 December 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Acute thrombotic or thromboembolic occlusion (onset of pain < 14 days)
- Age > 18 years
- Written informed consent form
Who cannot take part
- Known, unhealed pre-existing mechanical damage to the vessel wall, especially caused by surgical procedures or interventional complications
- Current participation in any other clinical study (medicinal, medical device) or within the last 30 days prior to screening
- Known or suspected allergy to any of the components of the system or to a medicinal product to be administered in connection with the planned procedure
- Severe coagulatory disorders
- Known or suspected infection, especially of the puncture site or the vessel segment being treated
- Patient not suitable for thrombectomy
- Fracture area of broken stents
- Persistent vasospasm
- Patients with thrombophilia
- Aneurysmatically altered vessel segments on target zone or on passage of catheter
- Immature or not fully healed dialysis accesses or bypass grafts
- Female subjects of childbearing capacity who are not willing to employ contraceptive measures
- Pregnant or breast feeding subjects
- Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this study or will not comply with requirements of the study
- Subjects who are lawfully kept in an institution
- Subjects who do not have the mental or physical ability to comply with time schedules and further study procedures
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The ASPIREX®S Endovascular System is a rotating and aspirating catheter system. It is intended to be used for the percutaneous transluminal removal of fresh thrombotic or thromboembolic material from native blood vessels (or vessels fitted with stents, stent grafts or native or artificial bypasses) outside the cardiopulmonary, coronary and cerebral circulations.
Read full original descriptionShow less
CAPTUREX® , a catheter with a filter basket, is intended to be used for the filtering of emboli from blood vessels during potentially embolizing procedures on the patient.
ASPIREX®S and CAPTUREX® are CE-marked (Class III) medical devices. In this study the effectiveness and safety in the removal of thrombi in veins is assessed under real life setting.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Post-Market Clinical Follow-up Study with the ASPIREX®S Endovascular System to Assess the Safety and Effectiveness in the Treatment of DVT Patients and Special Patient Groups
- Record updated
- 3 December 2024